Position in NVS
as of Jun 30, 2026
· filed Jul 22, 2026
Position Value
$2,006,016
+$299,035 QoQ
Shares Held
12,800
+14.5% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.46%
of 13F equity value
Holder Rank
#431
of 1,603 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026TrueMark Investments, LLC holds $39,739,215 across 7 Drug Manufacturers - General names. NVS ranks #6 (5.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
50,803 | $12,902,437 | |
| 2 | ABBV |
AbbVie Inc.
|
37,043 | $9,321,500 | |
| 3 | GSK |
GSK plc
|
108,899 | $5,708,485 | |
| 4 | SNY |
Sanofi
|
125,869 | $5,369,571 | |
| 5 | AZN |
Astrazeneca PLC
|
18,998 | $3,602,400 | |
| 6 | NVS |
Novartis AG
This page
|
12,800 | $2,006,016 | |
| 7 | LLY |
ELI LILLY & Co
|
691 | $828,806 |
All Filings in NVS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,006,016 | 12,800 | Shares | Sole | 2026-07-22 | |
| 2026-03-31 | $1,706,981 | 11,175 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $1,351,126 | 9,800 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $1,093,246 | 8,525 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $898,499 | 7,425 | Shares | Sole | 2025-07-29 | |
| 2025-03-31 | $699,537 | 6,275 | Shares | Sole | 2025-04-22 | |
| No filing history on record for this holder in this stock. | ||||||